Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00034827 |
CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.
Condition | Intervention | Phase |
---|---|---|
Colorectal Neoplasms Breast Neoplasms Carcinoma, Non-Small-Cell Lung Pancreatic Neoplasms |
Drug: CI-1040 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Pfizer Investigational Site | |
Birmingham, Alabama, United States, 35205 | |
Pfizer Investigational Site | |
Birmingham, Alabama, United States, 35233 | |
United States, California | |
Pfizer Investigational Site | |
Los Angeles, California, United States, 90048 | |
Pfizer Investigational Site | |
Blendora, California, United States, 91740 | |
Pfizer Investigational Site | |
Glendale, California, United States, 91204 | |
Pfizer Investigational Site | |
Huntington Beach, California, United States, 92648 | |
Pfizer Investigational Site | |
Long Beach, California, United States, 90813 | |
Pfizer Investigational Site | |
Rancho Cucamonga, California, United States, 91730 | |
Pfizer Investigational Site | |
Los Angeles, California, United States, 90095 | |
Pfizer Investigational Site | |
Mission Hills, California, United States, 91345 | |
Pfizer Investigational Site | |
Northridge, California, United States, 91328 | |
Pfizer Investigational Site | |
Oxnard, California, United States, 93030 | |
Pfizer Investigational Site | |
Pasadena, California, United States, 91105 | |
Pfizer Investigational Site | |
Pomona, California, United States, 91767 | |
Pfizer Investigational Site | |
Los Alamitos, California, United States, 90720 | |
Pfizer Investigational Site | |
Redondo Beach, California, United States, 90277 | |
Pfizer Investigational Site | |
Santa Monica, California, United States, 90404 | |
Pfizer Investigational Site | |
Torrance, California, United States, 90505 | |
Pfizer Investigational Site | |
Ventura, California, United States, 93003 | |
Pfizer Investigational Site | |
West Covina, California, United States, 91790 | |
United States, Georgia | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
Pfizer Investigational Site | |
Decatur, Georgia, United States, 30033 | |
Pfizer Investigational Site | |
Macon, Georgia, United States, 30342 | |
United States, Kentucky | |
Pfizer Investigational Site | |
Crestview Hills, Kentucky, United States, 41017 | |
United States, Michigan | |
Pfizer Investigational Site | |
Detroit, Michigan, United States, 48201 | |
United States, Minnesota | |
Pfizer Investigational Site | |
Rochester, Minnesota, United States, 55905 | |
United States, Ohio | |
Pfizer Investigational Site | |
Cincinnait, Ohio, United States, 45236 | |
Pfizer Investigational Site | |
Cincinnati, Ohio, United States, 45242 | |
Pfizer Investigational Site | |
Cincinnati, Ohio, United States, 45230 | |
Pfizer Investigational Site | |
Cincinnati, Ohio, United States, 45219 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | 1040-000-002 |
Study First Received: | May 2, 2002 |
Last Updated: | May 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00034827 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Thoracic Neoplasms Gastrointestinal Diseases Pancreatic Neoplasms Colonic Diseases Rectal Diseases Respiratory Tract Diseases Lung Neoplasms Breast Diseases Endocrine Gland Neoplasms Digestive System Neoplasms Skin Diseases Breast Neoplasms Endocrine System Diseases |
Intestinal Diseases Intestinal Neoplasms Carcinoma Digestive System Diseases Lung Diseases Gastrointestinal Neoplasms Pancreatic Diseases Non-small Cell Lung Cancer Endocrinopathy Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Gastrointestinal Diseases Pancreatic Neoplasms Colonic Diseases Rectal Diseases Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Breast Diseases Endocrine Gland Neoplasms Respiratory Tract Neoplasms Neoplasms by Histologic Type Digestive System Neoplasms Skin Diseases |
Endocrine System Diseases Breast Neoplasms Intestinal Diseases Intestinal Neoplasms Carcinoma Neoplasms Digestive System Diseases Lung Diseases Pancreatic Diseases Gastrointestinal Neoplasms Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Neoplasms, Glandular and Epithelial |